Table 2. Product characterization... | American Society of Hematology

Table 2.

Product characterization

Patient ID	Percentage										SFC/1 × 10⁵ T cells					Fold expansion	Total no. of cells frozen
Patient ID	B cells	T cells	CD4⁺	CD8⁺	Natural Killer T-cells	Natural killer cells	CD3⁺ TCRab	CD3⁺ TCRgd	Mono	DCs	Actin	WT1	Prame	Survivin	TAA*	Fold expansion	Total no. of cells frozen
Patient 1	0	99.5	10.9	29.3	42	0.92	16.3	73.5	0.3	0	7	16	179.5	2	88	23.2	1.39e8
Patient 2	1.58	84.9	10.2	74.6	52.3	0.52	80.3	4.1	1.08	0.16	1	2.5	5	0	5.5	12.3	2.4510⁷
Patient 3	0	84.5	20	39	25	0.3	66	23.1	0	0	154.5	139	335	132.5	445	5	1.36e⁸
Patient 4	0.2	99.1	16.9	81.6	2.2	14.8	91.8	69	0.2	0	5.5	10.5	72.5	5	48	5.91	1e⁸
Patient 5	0.05	83.3	1.74	42.7	23.7	16.8	45.3	42.2	0.01	0.04	3.5	5	4	1	25.5	4.92	9.3510⁷
Patient 6	0.1	80.9	4.8	69.8	27.9	4.1	82.7	12.3	0	0	2.5	16	234	2	182.5	3.86	1.3910⁸
Patient 6_2	0	97.3	7.1	77	58.3	2.6	71.6	26	0	0	7.5	15	12	5	27	4.1	4.95 × 10⁷
Patient 7	0.07	96	20	75.7	45.1	1.1	87.4	11.5	0	0.02	18.5	24.5	15.5	30	20.5	5.57	1.3e⁸
Patient 7_2	0	99.3	10.4	85.4	1.44	0.17	94..1	4	0	0	5.5	1	3	6	9	1.83	1.7 × 10⁷
Patient 8	0.3	98	1.73	43.3	33.7	0.6	39.5	58	0.1	0	7.5	37	67	18	22	5.97	1.88e⁸
Patient 9	0.05	98.3	9.5	87.5	11.2	0	97.5	1.9	0	0.02	9.5	11	16	9	11.5	6.52	1.37e⁸
Patient 10	0.09	99.5	11.8	69.5	3.59	0	81.4	16.1	0	0	1.5	15.5	1	14	10.5	2.31	4.3810⁷

Patient ID	Percentage										SFC/1 × 10⁵ T cells					Fold expansion	Total no. of cells frozen
Patient ID	B cells	T cells	CD4⁺	CD8⁺	Natural Killer T-cells	Natural killer cells	CD3⁺ TCRab	CD3⁺ TCRgd	Mono	DCs	Actin	WT1	Prame	Survivin	TAA*	Fold expansion	Total no. of cells frozen
Patient 1	0	99.5	10.9	29.3	42	0.92	16.3	73.5	0.3	0	7	16	179.5	2	88	23.2	1.39e8
Patient 2	1.58	84.9	10.2	74.6	52.3	0.52	80.3	4.1	1.08	0.16	1	2.5	5	0	5.5	12.3	2.4510⁷
Patient 3	0	84.5	20	39	25	0.3	66	23.1	0	0	154.5	139	335	132.5	445	5	1.36e⁸
Patient 4	0.2	99.1	16.9	81.6	2.2	14.8	91.8	69	0.2	0	5.5	10.5	72.5	5	48	5.91	1e⁸
Patient 5	0.05	83.3	1.74	42.7	23.7	16.8	45.3	42.2	0.01	0.04	3.5	5	4	1	25.5	4.92	9.3510⁷
Patient 6	0.1	80.9	4.8	69.8	27.9	4.1	82.7	12.3	0	0	2.5	16	234	2	182.5	3.86	1.3910⁸
Patient 6_2	0	97.3	7.1	77	58.3	2.6	71.6	26	0	0	7.5	15	12	5	27	4.1	4.95 × 10⁷
Patient 7	0.07	96	20	75.7	45.1	1.1	87.4	11.5	0	0.02	18.5	24.5	15.5	30	20.5	5.57	1.3e⁸
Patient 7_2	0	99.3	10.4	85.4	1.44	0.17	94..1	4	0	0	5.5	1	3	6	9	1.83	1.7 × 10⁷
Patient 8	0.3	98	1.73	43.3	33.7	0.6	39.5	58	0.1	0	7.5	37	67	18	22	5.97	1.88e⁸
Patient 9	0.05	98.3	9.5	87.5	11.2	0	97.5	1.9	0	0.02	9.5	11	16	9	11.5	6.52	1.37e⁸
Patient 10	0.09	99.5	11.8	69.5	3.59	0	81.4	16.1	0	0	1.5	15.5	1	14	10.5	2.31	4.3810⁷

TAA represents spot-forming cells (SFC) per 1 × 10⁵ T cells in response to a mixture of WT1, PRAME, and Survivn added to the same experimental well.